Background: Cytomorphology alone is often insufficient for the diagnosis and subclassification of lymphomas, so flow cytometry (FC) may be used as an adjuvant test. Methods: Renal fine-needle aspirations (FNAs) performed from January 1993 to August 2014 were reviewed for FC data or a diagnosis of lymphoma. Results: A total of 586 renal FNAs were collected. Thirty-three cases (5.1%) had FC analysis. Lymphoma was diagnosed 35 times (6%), and FC was performed in 21 (60%) cases. Both cytomorphology and FC were consistent with lymphoma in 20 cases. Cytomorphology alone was diagnostic of lymphoma in 15 cases. In 28 cases, biopsy from the kidney or another site was diagnostic of lymphoma. One subsequent biopsy revealed that a kidney FNA, which showed no definitive morphologic or FC evidence of lymphoma, likely represented necrotic diffuse large B-cell lymphoma. Conclusion: FC is a useful adjuvant diagnostic test for renal FNAs, particularly for subclassification and confirmation of the diagnosis when there is insufficient material for immunohistochemistry. FC should be interpreted with caution when a sample is limited or when there is suspicion of Hodgkin lymphoma, and further work-up is warranted when cytomorphology suggests lymphoma but FC is negative.

Keywords:
Fine-needle aspiration, Flow cytometry, Kidney, Lymphoma, Hematopathology, Ancillary testing
1.
Volpe A, Finelli A, Gill IS, et al: Rationale for percutaneous biopsy and histologic characterization of renal tumors. Eur Urol 2012;62:491-504.
2.
Sahni VA, Silverman SG: Biospy of renal masses: when and why. Cancer Imaging 2009;9:44-45
3.
Renshaw AA, Cibas ES: Cytology: Diagnostic Principles and Clinical Correlates, ed 3. Philadelphia, Saunders Elsevier Inc., 2009, pp 403-413.
4.
Morel P, Dupriez B, Herbrecht R, et al: Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Group d'Etude des Lymphomes de l'Adulte. Br J Cancer 1994;70:154-159.
5.
National Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Non-Hodgkin Lymphoma. http://seer.cancer.gov/statfacts/html/nhl.html (accessed January 11, 2016).
6.
Demurtas A, Accinelli G, Pacchioni D, Godio L, Novero D, Bussolati G, Palestro G, Papotti M, Stacchini A: Utility of flow cytometry immunophenotyping in fine-needle aspirate cytologic diagnosis of non-Hodgkin lymphoma: a series of 252 cases and review of the literature. Appl Immunohistochem Mol Morphol 2010;18:311-322.
7.
Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds): WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Albany, WHO Publications Center, 2008, p 310.
8.
Levitt S, Cheng L, Du Puis M, Layfield L: Fine needle aspiration diagnosis of malignant lymphoma with confirmation by immunoperoxidase staining. Acta Cytol 1985;29:895-902.
9.
Oertel J, Oertel B, Kastner M, Lobek H, Huhn D: The value of immunocytochemical staining of lymph node aspirates in diagnostic cytology. Br J Haematol 1988;70:307-316.
10.
Tani EM, Christensson B, Porwit A, Skoog L: Immnocytochemical analysis and cytomorphological diagnosis on fine needle aspirates of lymphoproliferative diseases. Acta Cytol 1988;32:209-215.
11.
Pilotti S, Di Palma S, Alasio L, Bartoli C, Rilke F: Diagnostic assessment of enlarged superficial lymph nodes by fine needle aspiration. Acta Cytol 1993;37:853-866.
12.
Mathiot C, Decaudin D, Klijanienko J, et al: Fine-needle aspiration cytology combined with flow cytometry immunophenotyping is a rapid and accurate approach for the evaluation of suspicious superficial lymphoid lesions. Diagn Cytopathol 2006;34:472-478.
13.
Dunphy CH, Ramos R: Combining fine-needle aspiration and flow cytometric immunophenotyping in evaluation of nodal and extranodal sites for possible lymphoma: a retrospective review. Diagn Cytopathol 1997;16:200-206.
14.
Young NA, Al-Saleem TI, Ehya H, et al: Utilization of fine-needle aspiration cytology and flow cytometry in the diagnosis and subclassification of primary and recurrent lymphoma. Cancer Cytopathol 1998;84:252-261.
15.
Zardawi IM, Jain S, Bennet G: Flow-cytometric algorithm on fine-needle aspirates for the clinical workup of patients with lymphadenopathy. Diagn Cytopathol 1998;19:274-278.
16.
Nicol TL, Silberman M, Rosenthal DL, et al: The accuracy of combined cytopathologic and flow cytometric analysis of fine-needle aspirates of lymph nodes. Am J Clin Pathol 2000;114:18-28.
17.
Meda BA, Buss DH, Woodruff RD, et al: Diagnosis and subclassification of primary and recurrent lymphoma. The usefulness and limitations of combined fine-needle aspiration cytomorphology and flow cytometry. Am J Clin Pathol 2000;113:688-699.
18.
Siebert JD, Weeks LM, List LW, et al: Utility of flow cytometry immunophenotyping for the diagnosis and classification of lymphoma in community hospital clinical needle aspiration/biopsies. Arch Pathol Lab Med 2000;124:1792-1799.
19.
Liu K, Stern RC, Rogers RT, et al: Diagnosis of hematopoietic processes by fine-needle aspiration in conjunction with flow cytometry: a review of 127 cases. Diagn Cytopathol 2001;24:1-10.
20.
Dong HY, Harris NL, Preffer FI, et al: Fine-needle aspiration biopsy in the diagnosis and classification of primary and recurrent lymphoma: a retrospective analysis of the utility of cytomorphology and flow cytometry. Mod Pathol 2001;14:472-481.
21.
Zeppa P, Marino G, Troncone G, et al: Fine-needle cytology and flow cytometry immunophenotyping and subclassification of non-Hodgkin lymphoma. A critical review of 307 cases with technical suggestions. Cancer 2004;102:55-65.
22.
Mourad WA, Tulbah A, Shoukri M, et al: Primary diagnosis and REAL/WHO classification of non-Hodgkin's lymphoma by fine-needle aspiration: cytomorphologic and immunophenotypic approach. Diagn Cytopathol 2003;28:191-195.
23.
Sigstad E, Dong HP, Davidson B, et al: The role of flow cytometric immunophenotyping in improving the diagnostic accuracy in referred fine-needle aspiration specimens. Diagn Cytopathol 2004;31:159-163.
24.
Laane E, Tani E, Björklund E, et al: Flow cytometric immunophenotyping including Bcl-2 detection on fine needle aspirates in the diagnosis of reactive lymphadenopathy and non-Hodgkin's lymphoma. Cytometry B Clin Cytom 2005;64:34-42.
25.
Caraway NP: Strategies to diagnose lymphoproliferative disorders by fine-needle aspiration by using ancillary studies. Cancer 2005;105:432-442.
26.
Jorgenson JL: State of the Art Symposium: flow cytometry in the diagnosis of lymphoproliferative disorders by fine-needle aspiration. Cancer 2005;105:443-451.
27.
Dey P: Role of ancillary techniques in diagnosing and subclassifying non-Hodgkin's lymphomas on fine needle aspiration cytology. Cytopathology 2006;17:75-287.
28.
Hanson CA: Fine-needle aspiration and immunophenotyping. A role in diagnostic hematopathology? Am J Clin Pathol 1994;101:555-556.
29.
Wakely PE: Fine-needle aspiration cytopathology in diagnosis and classification of malignant lymphoma: accurate and reliable? Diagn Cytopathol 2000;22:120-125.
30.
Cha C, Chen H, Westra WH, Udelsman R: Primary thyroid lymphoma: can the diagnosis be made solely by fine-needle aspiration? Ann Surg Oncol 2002;9:298-302.
31.
Subhawong AP, Subhawong TK, VandenBussche CJ, Siddiqui MT, Ali SZ: Lymphoproliferative disorders of the kidney on fine-needle aspiration: cytomorphology and radiographic correlates in 33 cases. Acta Cytol 2013;57:19-25.
32.
Katz RL, Hirch-Ginsberg C, Childs C, et al: The role of gene rearrangement for antigen receptors in the diagnosis of lymphoma obtained by fine-needle aspiration: a study of 63 cases with concomitant immunophenotyping. Am J Clin Pathol 1991;96:479-490.
33.
Trpkov K, Marcussen N, Rayner D, et al: Kidney allograft with a lymphocytic infiltrate: acute rejection, posttransplantation lymphoproliferative disorder, neither, or both entities? Am J Kidney Dis 1997;30:449-454.
34.
Goral S, Felgar R, Shappell S: Posttransplantation lymphoproliferative disorder in a renal allograft recipient. Am J Kidney Dis 1997;30:301-307.
35.
LeMeur Y, Potelune N, Jaccard A, et al: Lymphoproliferative syndromes after renal transplantation. Nephrologie 1998;19:255-261.
36.
Dimopoulos MA, Moulopoulos LA, Constantinides C, et al: Primary renal lymphoma: a clinical and radiological study. J Urol 1996;155:1865-1867.
37.
Siddiqui MT, Reddy VB, Castelli MJ, et al: Role of fine-needle aspiration in clinical management of transplant patients. Diagn Cytopathol 1997;17:429-435.
38.
Niaudet P: Posttransplant lymphoproliferative disease following renal transplantation: a multicenter retrospective study of 41 cases observed between 1992 and 1996. French Speaking Transplantation Workshop. Transplant Proc 1998;30:2816-2817.
39.
Chadburn A, Cesarman E, Knowles DM: Molecular pathology of posttransplantation lymphoproliferative disorders. Semin Diagn Pathol 1997;14:15-26.
40.
Randhawa PS, Magnone M, Jordan M, et al: Renal allograft involvement by Epstein-Barr virus associated post-transplant lymphoproliferative disease. Am J Surg Pathol 1996;20:563-571.
41.
Katz RL: Kidneys, adrenals and retroperitoneum; in Bibbo M (ed): Comprehensive Cytopathology, ed 2. Philadelphia, Saunders, 1997, pp 781-797.
42.
Renshaw AA, Granter SR, Cibas ES: Fine needle aspiration of the adult kidney. Cancer 1997;81:71-88.
43.
Gattuso P, Ramzy I, Truong LD, et al: Utilization of fine-needle aspiration in diagnosis of metastatic tumors to the kidney. Diagn Cytopathol 1992;21:35-38.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.